XML 51 R41.htm IDEA: XBRL DOCUMENT v3.19.2

Segments (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Segment Profit

a. Segment information:

		Three months ended June 30, 2019
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,071			$	1,183			$	741
Gross profit			1,067				674				312
R&D expenses			175				70				24
S&M expenses			269				216				119
G&A expenses			117				70				34
Other (income) expense			2				1				(1	)
Segment profit		$	504			$	316			$	136
		Three months ended June 30, 2018
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,263			$	1,328			$	789
Gross profit			1,179				727				328
R&D expenses			182				73				25
S&M expenses			272				233				130
G&A expenses			103				78				37
Other (income) expense			(100	)			(3	)			(3	)
Segment profit		$	722			$	346			$	139

		Six months ended June 30, 2019
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	4,118			$	2,448			$	1,409
Gross profit			2,107				1,404				582
R&D expenses			340				136				46
S&M expenses			537				431				234
G&A expenses			230				119				70
Other (income) expense			(2	)			(1	)			(1	)
Segment profit		$	1,001			$	719			$	233
		Six months ended June 30, 2018
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	4,794			$	2,770			$	1,539
Gross profit			2,582				1,519				641
R&D expenses			370				146				49
S&M expenses			548				483				264
G&A expenses			229				169				78
Other (income) expense			(202	)			(2	)			(11	)
Segment profit		$	1,637			$	723			$	261

Schedule Of Consolidated Income Before Income Tax

		Three months ended								Six months ended
		June 30,								June 30,
		2019				2018				2019				2018
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	504			$	722			$	1,001			$	1,637
Europe profit			316				346				719				723
International Markets profit			136				139				233				261
Total segment profit			956				1,207				1,954				2,621
Profit of other activities			55				31				76				52
			1,011				1,238				2,029				2,673
Amounts not allocated to segments:
Amortization			285				302				568				612
Other assets impairments, restructuring and other items			101				194				103				695
Goodwill impairment			—				120				—				300
Intangible asset impairments			561				521				1,030				727
(Gain) loss on divestitures, net of divestitures related costs			(9	)			10				(9	)			(83	)
Other R&D expenses			§				—				§				22
Costs related to regulatory actions taken in facilities			12				4				16				5
Legal settlements and loss contingencies			646				20				703				(1,258	)
Other unallocated amounts			59				81				129				142
Consolidated operating income (loss)			(644	)			(14	)			(510	)			1,511
Financial expenses, net			206				236				425				507
Consolidated income (loss) before income taxes		$	(850	)		$	(250	)		$	(934	)		$	1,004

§ Represents an amount less than $1 million​​​​​​​.

Schedule of Net Sales by Product Line

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three months and the six months ended June 30, 2019 and 2018:

		Three months ended June 30,
		2019				2018
		(U.S. $ in millions)
North America
Generic products		$	946			$		947
COPAXONE			274					464
TREANDA/BENDEKA			115					160
ProAir*			65					115
QVAR			60					30
AJOVY			23					—
AUSTEDO			96					44
Anda			351					320
Other			141					183
Total		$	2,071			$		2,263

		Six months ended
		June 30,
		2019				2018
		(U.S. $ in millions)
North America
Generic products		$	1,913			$	2,035
COPAXONE			482				940
TREANDA/BENDEKA			229				341
ProAir*			123				245
QVAR			124				137
AJOVY			43				—
AUSTEDO			171				74
Anda			729				651
Other			305				372
Total		$	4,118			$	4,794

		Three months ended June 30,
		2019				2018
		(U.S. $ in millions)
Europe
Generic products		$	844			$	907
COPAXONE			107				140
Respiratory products			89				106
Other			143				175
Total		$	1,183			$	1,328

		Six months ended June 30,
		2019				2018
		(U.S. $ in millions)
Europe​​​​​​​
Generic products		$	1,763			$	1,904
COPAXONE			221				293
Respiratory products			181				219
Other			283				354
Total		$	2,448			$	2,770

		Three months ended June 30,
		2019				2018
		(U.S. $ in millions)
International markets
Generic products		$	489			$	537
COPAXONE			13				22
Distribution			164				154
Other			75				76
Total		$	741			$	789

		Six months ended June 30,
		2019				2018
		(U.S. $ in millions)
International markets
Generic products		$	930			$	1,025
COPAXONE			27				38
Distribution			315				307
Other			137				168
Total		$	1,409			$	1,539

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration